Latest DCIS Stories
Positive Results of Largest Genomic Study in DCIS Reconfirm Oncotype DX is a Strong, Independent Predictor of Local Recurrence SAN ANTONIO, Dec.
Landmark Study Reconfirms Oncotype DX® Stratifies DCIS Patient Risk REDWOOD CITY, Calif., Dec. 2, 2014 /PRNewswire/ -- Genomic Health, Inc.
Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif., Sept.
New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc.
13% Increase in Test Volume and 7% Increase in Product Revenue Compared to Prior Year REDWOOD CITY, Calif., May 6, 2014 /PRNewswire/ -- Genomic Health, Inc.
New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS) REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/
Cianna Medical, Inc.: Strut-based breast cancer radiation treatment could expand options for DCIS patients. Aliso Viejo, Calif.
Ductal carcinoma in situ (DCIS), a noninvasive breast cancer that some doctors are now arguing is over-treated, needs to be evaluated according to each woman’s risk, and more research is needed
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS).
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).